Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-Small Cell Lung Cancer

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed clinical stage IB - IIIA
non-small cell lung cancer; stage IV patients with oligometastatic disease with
metastases that have been treated definitively with radiation or surgery are also
eligible (ie: solitary brain or adrenal metastasis); mixed tumors will be categorized
by the predominant cell type unless small cell elements are present in which case the
patient is ineligible; note: tissue samples from biopsy confirmation will be required

- Patients must be surgically resectable as determined by a thoracic surgeon

- Patients must have measurable disease per RECIST 1.1, defined as at least one lesion
that can be accurately measured in at least one dimension (longest diameter to be
recorded) as >= 10 mm with spiral CT scan

- Life expectancy of greater than 12 weeks

- ECOG performance status < 1

- Leukocytes >= 3,000/uL

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin =< 1.5 x institutional upper limit of normal

- AST (SGOT) =< 1.5 x institutional upper limit of normal

- Alkaline phosphatase =< 2.5 x institutional upper limit of normal

- Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 60
mL/1.73 m2 for patients with creatinine levels above institutional normal

- Fasting screening blood glucose =< 200 mg/dL

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with either agent

Exclusion Criteria:

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately

- Patients may not be receiving any other investigational agents

- Patients must not have received prior systemic chemotherapy or radiation therapy for
lung cancer; prior systemic chemotherapy or radiation for other malignancies over
three years prior to study enrollment may be allowed at the discretion of the
principal medical investigator

- Prior malignancy in the past 3 years, other than non-melanoma skin cancer and in situ
carcinoma of the cervix

- Patients who report a hearing deficit at baseline, even if it does not require a
hearing aid or intervention, or interfere with activities of daily life (Common
Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher)

- Peripheral neuropathy > CTCAE grade 1

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to cisplatin, docetaxel, or other agents used in the study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, uncontrolled diabetes, symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric/social situations that would
limit compliance with study requirements

- HIV-positive patients on combination antiretroviral therapy are ineligible

- Inability to comply with study and/or follow-up procedures